Who
Daniel J. Curran
Director
Company insider
Files Form 4 as: Director, Catalyst Pharmaceutical; Director, Xilio Therapeutics; Director, ALX Oncology Holdings.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 14 Jun 2024
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —18,115 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —5,468 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —18,115 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,468 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,833 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,833 at $0.00 | filing |
| 20 Nov 2025filed 24 Nov 2025 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —18,115 at $0.00 | filing |
| 20 Nov 2025filed 24 Nov 2025 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —5,468 at $0.00 | filing |
| 12 Aug 2025filed 13 Aug 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.